Genenta Science SpA ADR(GNTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.37 | Insider Own | - | Shs Outstand | 23.4M | Perf Week | -1.86% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -23.07% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 2.59% | Short Float | - | Perf Quarter | -56.15% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -16.35% | Short Ratio | 2.01 | Perf Half Y | -15.3% |
| Sales | 0.00B | P/B | 0.56 | EPS next 5Y | - | ROA | -27.77% | Short Interest | 0.11M | Perf YTD | -58.5% |
| Book/sh | 1.09 | P/C | 0.9 | EPS past 3/5Y | 8.56% -1.23% | ROE | -38% | 52W High | -80.37% ($3.15) | Perf Year | -78.46% |
| Cash/sh | 0.69 | P/FCF | - | Sales past 3/5Y | - | ROIC | -21.2% | 52W Low | 12.42% ($0.55) | Perf 3Y | -87.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 29.62% | Gross Margin | - | Volatility(W/M) | 7.09% 7.65% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.16 | EPS Q/Q | 48.49% | Profit Margin | - | RSI (14) | 36.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.16 | Sales Q/Q | - | SMA20 | -8.45% ($0.68) | Beta | 0.76 | Target Price | $6.94 |
| Payout | - | Debt/Eq | 0.35 | Earnings | 2026/7/22 | SMA50 | -21.86% ($0.79) | Rel Volume | 1.25 | Prev Close | $0.62 |
| Employees | 9 | LT Debt/Eq | 0.35 | EPS/Sales Surpr. | - | SMA200 | -40.44% ($1.04) | Avg Volume(3M) | 0.05M | Price | $0.62 |
| IPO | 2021/12/15 | Option/Short | No/Yes | Trades | 130 | Volume | 67,198 | Change | -0.27% |
🧬 Genenta Science () is a clinical-stage immuno-oncology biotech headquartered in Italy. The company develops its lead candidate, <strong>Temferon™</strong>, which genetically modifies a patient's hematopoietic stem cells to trigger an immune response within the tumor microenvironment, with solid tumors such as glioblastoma and metastatic renal cell carcinoma as its primary targets.
Over the past 1 year, on the lower side
80% below its 1-year high.
Traded about as much as usual. That is 125% of its average volume.
GNTA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -87.6%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.6%.
Tap to view numbers
It ranks #24 of 28 in the industry
Based on market cap of $30M.
AIRT#22 Air T Inc $75M PER 1.2 
GPUS#23 Hyperscale Data Inc $31M PER - GNTA#24 Genenta Science SpA ADR $30M PER - 
HHS#25 Harte-Hanks Inc $29M PER - 
LGPS#26 LogProstyle Inc $15M PER 3.0 
FAQ
What kind of company is GNTA?
GNTA belongs to the Industrials sector and operates in the Conglomerates industry.
What is the market cap of GNTA?
The market cap of GNTA is approximately $30M, ranking 5,070 within its sector.
What is the 52-week high and low for GNTA?
GNTA has recorded a 52-week high of $3.15 and a low of $0.55.
